Cigna Healthcare classified HCPCS code C9777 for mucosal integrity testing as Experimental/Investigational/Unproven under policy MM 0577, effective October 16, 2025. Here's what billing teams need to do.
Cigna Healthcare updated its Cigna mucosal integrity testing coverage policy under MM 0577 in the MM 0577 Cigna system, covering esophageal mucosal integrity testing via transoral electrical impedance — specifically the MiVu™ Mucosal Integrity Testing System. The single code affected is HCPCS C9777. If your practice or facility bills C9777 for esophagoscopy or esophagogastroduodenoscopy (EGD) with electrical impedance testing, Cigna will not reimburse it. This is a firm denial position, not a prior authorization hurdle.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Mucosal Integrity Testing — MM 0577 |
| Policy Code | MM 0577 |
| Change Type | Modified |
| Effective Date | October 16, 2025 |
| Impact Level | High — all claims for C9777 will deny |
| Specialties Affected | Gastroenterology, General Surgery, Hospital Outpatient |
| Key Action | Stop billing C9777 to Cigna; recode or redirect testing to covered alternatives before submitting claims |
Cigna Mucosal Integrity Testing Coverage Criteria and Medical Necessity Requirements 2025
The short answer: Cigna does not recognize HCPCS C9777 as medically necessary. The Cigna mucosal integrity testing coverage policy under MM 0577 treats the MiVu™ system — and by extension, any esophageal mucosal integrity test billed with C9777 — as experimental, investigational, and unproven.
This means the payer does not accept clinical evidence supporting C9777's use as sufficient to establish medical necessity for coverage purposes. It does not matter whether the patient has a documented diagnosis of GERD, Barrett's esophagus, or eosinophilic esophagitis. The coverage position applies regardless of diagnosis.
There is no prior authorization pathway for C9777 under this policy. You cannot get a prior auth approved and then bill. Cigna's experimental/investigational designation blocks coverage entirely — prior authorization is irrelevant when the service is categorically excluded. If your team has been seeking prior auth for this code, stop. The denial will come regardless.
The MiVu™ system uses electrical impedance measurements taken during standard upper endoscopy to assess mucosal barrier function. Cigna's position is that clinical evidence has not yet proven this testing changes patient outcomes or guides treatment decisions in a meaningful way. That's the bar the payer is applying — and as of October 16, 2025, C9777 does not clear it.
Cigna Mucosal Integrity Testing Exclusions and Non-Covered Indications
HCPCS C9777 is the only code addressed in this coverage policy, and it carries a single coverage status: Experimental/Investigational/Unproven. There are no covered indications listed. There are no patient subpopulations for whom Cigna will reimburse this service.
The full description for C9777 is: Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy. Cigna's position covers the entire code — the bundled endoscopy component and the impedance testing component together.
This is an important nuance for mucosal integrity testing billing. The endoscopy itself (when billed separately with standard EGD codes) may be covered. The issue is specifically the electrical impedance mucosal integrity component billed under C9777. If your team is bundling C9777 with a standard endoscopy encounter, you need to separate what's covered from what isn't before the claim goes out.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Esophageal mucosal integrity testing by electrical impedance, transoral (MiVu™ system), includes esophagoscopy or EGD | Experimental / Investigational / Unproven | C9777 | No covered indications. No prior authorization pathway. Claims will deny regardless of diagnosis. |
Cigna Mucosal Integrity Testing Billing Guidelines and Action Items 2025
The effective date is October 16, 2025. If your team has already submitted claims with C9777 to Cigna after that date, pull those claims now and assess your exposure.
| # | Action Item |
|---|---|
| 1 | Audit all C9777 claims submitted to Cigna on or after October 16, 2025. Pull a remittance report filtered by HCPCS C9777 and payer Cigna. Any claim submitted after the effective date is at high risk of denial or recoupment if paid in error. |
| 2 | Remove C9777 from your Cigna charge capture workflows immediately. If your EHR or practice management system has charge capture rules or order sets that trigger C9777 for Cigna patients, flag those for revision. Your billing team should not be generating C9777 claims for Cigna-covered patients. |
| 3 | Do not submit C9777 with a prior authorization number expecting reimbursement. The experimental designation overrides prior auth. A Cigna prior auth for this service has no value under this coverage policy. If a provider received a prior auth for C9777 before October 16, 2025, verify whether that auth is still honored or whether the policy update voids it — call Cigna Provider Services directly to confirm. |
| 4 | Evaluate whether the underlying endoscopy is separately billable. If the patient underwent esophagoscopy or EGD as part of the encounter, that procedure may be billable under standard endoscopy codes without C9777. Review the documentation to determine whether the endoscopy stands alone as a covered service. Your coding team needs to review the operative report before re-coding. |
| 5 | Have a conversation with any gastroenterology or GI surgery providers who order MiVu™ testing. They need to know that Cigna will not cover this for their patients. If patients are being counseled about testing options, Cigna-covered patients should understand this is a non-covered service before the procedure happens — not after. A non-covered service disclosure and patient financial responsibility form is appropriate here. |
| 6 | Document your process for handling C9777 denials. When denials come in on C9777 claims already in the pipeline, your team needs a clear workflow. Cigna denial reason codes tied to experimental/investigational designations typically do not support successful appeals without new clinical evidence — but you can appeal if you believe the service was miscoded or the denial reason is incorrect. Track denial volume on this code and report it to your billing director. |
| 7 | Talk to your compliance officer before the end of October 2025. If your facility has been billing C9777 routinely and collecting reimbursement from Cigna, you need to assess whether any paid claims need to be reviewed for accuracy. Your compliance officer should determine whether a look-back is warranted. This is not generic advice — the MiVu™ system is a specific proprietary technology, and if your facility has been an early adopter, your Cigna claim volume on C9777 may be material. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Mucosal Integrity Testing Under MM 0577
This policy addresses one HCPCS code. No CPT codes or ICD-10 diagnosis codes are listed in the MM 0577 policy document.
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| C9777 | HCPCS | Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy | Considered Experimental/Investigational/Unproven by Cigna Healthcare |
CPT Codes
No CPT codes are listed in the policy data for MM 0577. Do not substitute CPT codes for C9777 — this is a HCPCS C-code assigned specifically to the MiVu™ technology. Substituting an unlisted endoscopy CPT code is not an appropriate workaround and creates its own coding accuracy risk.
ICD-10-CM Diagnosis Codes
MM 0577 does not specify ICD-10 diagnosis codes. The experimental designation applies regardless of the diagnosis code submitted on the claim.
A note on the HCPCS C-code structure: C-codes are typically used in hospital outpatient settings and are assigned by CMS for new technologies that don't yet have a permanent CPT code. C9777 follows that pattern. If CMS eventually assigns a permanent CPT code for electrical impedance mucosal integrity testing, Cigna's coverage position under MM 0577 will need to be revisited. Until then, C9777 is the operative code — and it's blocked.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.